19 / 24
Notes:
Volume 7, Issue 6 (Suppl)
J Gastrointest Dig Syst, an open access journal
ISSN: 2161-069X
Page 45
December 07-08, 2017 Madrid, Spain
&
13
th
International Conference on Clinical Gastroenterology & Hepatology
2
nd
International Conference on Digestive Diseases
CO-ORGANIZED EVENT
Adjuvant chemotherapy after neoadjuvant chemoradiation in esophageal cancer: Apropensity score
matched analysis
Juan F Ricardo
1
, Talal Alkayali
1
, Ahmed Salem
1
and
Kenneth L Meredith
2
1
Florida State University - Sarasota Memorial Hospital, USA
2
Sarasota Memorial Hospital, USA
Purpose:
Patients with locally advanced esophageal cancer (EC) have poor long-term survival despite improvements in
multi-modality care. Neoadjuvant chemoradiation (NCR) followed by surgical resection remains standard of care. However,
the utilization of adjuvant therapy continues to be debated. Our study reviews the effectiveness of adjuvant therapy after
neoadjuvant therapy in resected EC.
Methods:
Utilizing the National Cancer Database (NCDB) we identified patients with esophageal cancer who underwent
NCR followed by esophagectomy and compared patients who received adjuvant therapy to those who did not. Propensity
score matched (PSM) analysis was performed and baseline univariate comparisons of patient characteristics were made for
continuous variables using both the Mann-Whitney U and Kruskal Wallis tests as appropriate. Pearson’s Chi-square test
was used to compare categorical variables. Unadjusted survival analyses were performed using the Kaplan-Meier method
comparing survival curves with the log-rank test. All statistical tests were two-sided and α (type I) error <0.05 was considered
statistically significant.
Results:
We identified 1,816 patients with EC: adenocarcinoma n=1,664 (91.6%) and squamous cell carcinoma n=134 (7.4%).
There were 1,596 (87.9%) males and 220 (12.1%) females. Location of the tumor was 121 (6.7%) middle, 1,267 (7.0%) lower, and
371 (20.4%) at the gastroesophageal junction. Both the adjuvant therapy group and the no adjuvant group had 908 patients after
PSM with a median age of 60 years (26-83). Univariate analysis revealed age, R0 resection, T-stage, N-stage, grade, <10 lymph
nodes removed and adjuvant therapy were predictors of survival. All patients who received adjuvant therapy revealed greater
median and overall survival, 36.4 months and 34.5% versus 30.9 months and 33.2%, p=0.02. Node negative patients did not
show a significance in survival with adjuvant therapy 57.2 and 55.4 months respectively, p=0.4. However node positive patients
demonstrated improved median and overall survival with adjuvant therapy 31.1 months and 27% respectively compared to
the no adjuvant therapy group 25.7 months and 24.3%, p=0.03. Multivariate analysis revealed LN+, T-stage (p=0.002), R0
resection (p<0.001), and number of lymph nodes removed (p<0.001) were predictors of survival.
Conclusion:
Adjuvant therapy in all EC patients after neoadjuvant therapy does show improved median and overall survival.
Similar to other studies, R0 resection and T-stage continue to influence survival. However, node negative EC patients were
found to have no survival benefit with the addition of adjuvant therapy.
Biography
Juan F Ricardo is a resident physician of internal medicine at Florida State University – Sarasota Memorial Hospital in Sarasota, Florida, USA. His main area of
interest is gastroenterology
juan-ricardo@smh.comJuan F Ricardo et al., J Gastrointest Dig Syst 2017, 7:6(Suppl)
DOI: 10.4172/2161-069X-C1-058